论文部分内容阅读
骨是前列腺癌最常见的远处转移部位,超过80%的前列腺癌患者发生骨转移。晚期骨转移严重影响患者的生存质量,同时也是导致其死亡的重要因素。镭-223(Ra-223)是最近批准上市用于治疗骨转移性前列腺癌的新药,具有既能改善患者生活质量,又能延长患者总体生存期的优势。本文将对近年来Ra-223治疗前列腺癌骨转移临床研究进展作一综述。
Bone is the most common distant metastasis of prostate cancer, and bone metastases occur in more than 80% of prostate cancer patients. Late bone metastases seriously affect the quality of life of patients, but also an important factor leading to its death. Radium-223 (Ra-223) is a newly approved new drug for the treatment of bone metastatic prostate cancer. It has the advantage of improving the quality of life of patients and prolonging the overall survival of patients. This article will review recent progress in Ra-223 treatment of prostate cancer bone metastases.